Improving clinical outcomes with drug treatment in heart failure: what have trials taught? (Q35096839)

6 August 2017

1 reference

title

Improving clinical outcomes with drug treatment in heart failure: what have trials taught? (English)

1 reference

6 August 2017

1 reference

Marvin A Konstam

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

6A

1 reference

6 August 2017

page(s)

9D-14D

1 reference

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Progress in heart failure Management? Lessons from the real world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Effect of carvedilol on survival in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903374-X

10.1016/S0002-9149(02)03374-X

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference